Asthma is a complex disease characterised by airway inflammation, reversible airway obstruction and airway hyper-responsiveness. Symptoms include recurrent wheezing, shortness of breath, cough and chest tightness. Asthma continues to be a major health concern worldwide with a global prevalence of over 300 million (WHO 2018).
The STIFLE study aims to better understand the relationship between daily changes in inflammation, asthma symptoms, lung function tests and the use of asthma medication in asthma patients. The study involves using two medications, Symbicort® and Ventolin®, which are already approved treatments for asthma as both preventer and/or reliever therapies. The overall objective of this study is to determine whether SMART therapy (maintenance and reliever therapy) results in benefits in terms of reducing inflammation and symptoms.
The research team are looking for people who have been diagnosed with asthma for at least 6 months prior to the initial study visit. The participants should also be able to perform daily measurements at home using a devices connected to a smartphone (devices, smartphone and training provided).
For more information about this study please email [email protected] or call 01382 383235/383431.
To check your eligibility for this study please complete the short questionnaire below. If you wish to take part, please ensure that you register with SHARE on completion (even if you have done so already) to ensure that we can contact you.
